<DOC>
	<DOCNO>NCT00766337</DOCNO>
	<brief_summary>The purpose study determine safety efficacy ocular sirolimus ( rapamycin ) formulation combination Lucentis patient sub-foveal choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>Phase 2 Study Ocular Sirolimus ( Rapamycin ) Formulation Combination With Lucentis速 Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosed subfoveal choroidal neovascularization secondary agerelated macular degeneration within six month initial study visit , may treat 3 Lucentis速 ( ranibizumab ) 3 Avastin速 ( bevacizumab ) injection last injection administer least 4 week prior initial study visit , treatmentna誰ve Visual acuity 20/40 20/200 study eye Any ocular disease could compromise vision study eye Presence cause choroidal neovascularization secondary agerelated macular degeneration</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>wet AMD</keyword>
</DOC>